The report states that post better-than-expected Q2FY27 results, FY27 revenue/EBITDA/PAT estimates were revised upwards by 22%/41%/52% and FY28 estimates by 25%/45%/56%, with revenue/EBITDA/PAT expected to grow at a CAGR of 24%/37%/42% over FY26-28, while maintaining a HOLD rating.
Read this note →Deepak Nitrite Limited
NSE DEEPAKNTR BSE 506401 INE288B01029
0 filings · 0 analysed
1,540.00
-5.05%
over 1 month
-
The report states that post better-than-expected Q2FY27 results, FY27 revenue/EBITDA/PAT estimates were revised upwards by 22%/41%/52% and FY28 estimates by 25%/45%/56%, with revenue/EBITDA/PAT expected to grow at a CAGR of 24%/37%/42% over FY26-28, while maintaining a HOLD rating.
-
Deepak Nitrite Update Oct 26 HSIE
The report maintains a SELL rating on Deepak Nitrite with a revised target price of INR 1,532, citing limited near-term volume growth, rising leverage from debt-funded capex, and global oversupply in phenol and polycarbonate pressuring margins, with EPS CAGR expected at -9% over FY27-29E.
-
Chemicals Q2FY27 Results Preview HSIE
The report expects revenue to grow 31% YoY but EBITDA margin to fall 417bps QoQ to 16.8%; the rating was revised from SELL to REDUCE.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 14 Oct 2026, 15:45 | short | 1,645.40 | 1,460.00 | 1,446.80 | 107% | hit |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report maintains a SELL rating on Deepak Nitrite with a revised target price of INR 1,532, citing limited near-term volume growth, rising leverage from debt-funded capex, and global oversupply in phenol and polycarbonate pressuring margins, with EPS CAGR expected at -9% over FY27-29E.
Read this note →The report expects revenue to grow 31% YoY but EBITDA margin to fall 417bps QoQ to 16.8%; the rating was revised from SELL to REDUCE.
Read this note →The report says a subsidiary has commissioned its Chlorination & Specialty Chemicals plant in Gujarat with cumulative capex of ~₹300 crore, with a positive view.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief